RapidAI — Cyborg Score 8/10

Strong
Clinical AI & Drug Discovery

Strategic Profile

As a clinician-founded company, RapidAI ensures its tools meet practical needs by using curated datasets and advanced image processing techniques. Frost & Sullivan ranks RapidAI's enterprise platform ahead of 96% in the industry. RapidAI is used by more than 2,500 hospitals in over 100 countries and backed by 700+ clinical studies, including research that helped expand national stroke-treatment guidelines.

Cyborg Score Rationale

RapidAI demonstrates exceptional clinical validation, global market penetration, and strategic partnerships. The company has secured $100M in Series C funding and maintains strong competitive positioning with FDA clearances. Near-term growth drivers include AWS partnership (December 2025) and Saudi Arabia deployment (November 2025), though private company status limits financial transparency.

Top Insights

  • RapidAI's 'deep clinical AI' goes beyond simple triage to localize, quantify, and visualize disease states.
  • As of March 31, 2026, RapidAI employed 267 people.
  • Landmark clinical trials using Rapid imaging led to worldwide stroke guidelines expanding the treatment window from 6 to 24 hours.
  • RapidAI formed a strategic partnership with Health Holdings Company (HHC), Saudi Arabia's largest healthcare provider, to deploy AI across HHC's 20 health clusters (November 2025).

Named Competitors

  • Viz.ai — AI-enabled care coordination and medical imaging analysis for stroke and acute care
  • Brainomix — Clinical AI platform for stroke and neurological imaging analysis
  • Ambra Health — AI-powered medical imaging platform for stroke and acute care workflows
  • Aidoc — Clinical AI platform for medical imaging detection and prioritization
  • Subtle Medical — AI imaging analytics for advanced medical imaging workflows

Recent Developments

  • (December 2025) RapidAI strengthened relationship with AWS to accelerate global adoption, combining AWS's AI infrastructure with RapidAI's clinical expertise and healthcare data.
  • (November 2025) FDA clearance for five new deep clinical AI modules.
  • (November 2025) Strategic partnership with Health Holdings Company (HHC) in Saudi Arabia to deploy AI across 20 health clusters.
  • (April 2026) HCA Healthcare's Good Samaritan Hospital in San Francisco Bay Area became the first facility to deploy RapidAI's Lumina 3D, generating three-dimensional visualizations of blood vessels from CT scans within minutes to accelerate stroke diagnosis.

Open the full interactive RapidAI report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →